Navigation Links
Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takeda's DEXILANT®
Date:3/2/2011

release that refer to future events or other non-historical facts are forward-looking statements that reflect Handa's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Handa disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Handa's current expectations depending upon a number of factors affecting Handa's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and demand for Handa's products; difficulties or delays in manufacturing; and other risks and uncertainties.

DEXILANT® is a registered trademark of Takeda Pharmaceuticals North America, Inc.

SEROQUEL® and SEROQUEL XR® are registered trademarks of the AstraZeneca group of companies.Company Contact: Stephen CaryExecutive Vice President and COO Handa Pharmaceuticals, LLC(510) 354-2888stephen.cary@handapharma.comhttp://www.handapharma.comThis press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Handa Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
2. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
3. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
4. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
5. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
6. Access Pharmaceuticals to Host Update Conference Call for Investors
7. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
8. Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results Conference Call on March 7
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
11. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients with ... ibrutinib may be effective and generally well-tolerated in patients ... separate study examining the safety and efficacy of ibrutinib ...
(Date:6/19/2013)... BRAINTREE, Mass. , June 19, 2013 /PRNewswire/ ... announced several important developments in the pursuit of ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , ... SANM ) for the future production of medical ... , Massachusetts. Sanmina is a leading global provider of ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- Robert M. Bernstein, M.D., ... procedures and founder of Bernstein Medical – Center ... Doctors, issue of New York Magazine for the ... ) Dr. Bernstein earned his ... reputation as world-renowned hair restoration physician, through a ...
Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
... 27 Kinex Pharmaceuticals will present results from a Phase ... Meeting in Orlando, on May 29, 2009. The study ... (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, ... "Results of a phase I trial of KX2-391, a novel ...
... Administered in Dual Cord Blood Transplant for Hematologic MalignancyLA JOLLA, ... announced today that the first patient has been treated ... molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem ... pathways that guide cell fate. The study, which is ...
Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4
(Date:6/19/2013)... Santiago, Chile (PRWEB) June 20, 2013 ... Chile Montaña has put together their winter season ... of outdoor adventure day trips in and around Santiago ... lead trips into Chile's Central Andes for backcountry skiing, ... , For those who have always dreamed of ...
(Date:6/19/2013)... (PRWEB) June 20, 2013 Everyone is looking for ... and inexpensive way to do so. It is called Skin ... - only 5 minutes per day - to improve health and ... improves general health. How? , Skin Brushing improves general health ... it aids the lymphatic system to drain toxins , ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Paleo Burn ... thousands of people finally sculpt the body they desire with ... other fat loss programs and health food products, Ken Smith ... and finally give consumers an easy, automatic, and permanent solution ... all the details . , After a quick review of ...
(Date:6/19/2013)... Brand new Hypertrophy Max bonus just released by Vince Del Monte ... Max program. Vince and Ben are only making this bonus ... must act quickly. , What is the all new Hypertrophy Max ... 12 month all access pass to the Live Large TV program ... TV is a Monday night show where over 4,000 members from ...
(Date:6/19/2013)... Shreya Rangarajan of Roland Park Country ... on the future of medicine. , Today, Brandeis ... Summit on the Future of Medicine and has selected ... the state of Maryland at the Summit. , "The ... an environment hard to imagine just a few years ...
Breaking Medicine News(10 mins):Health News:Chile Montaña Announces Winter Season Santiago Day Trips 2Health News:Chile Montaña Announces Winter Season Santiago Day Trips 3Health News:A Fast and Fun Way to Better Skin Quality and Overall Health, says Sublime Beauty® 2Health News:Paleo Burn Review Released by TotalWellnessCleanse.net 2Health News:New Hypertrophy Max Bonus Just Released and Only Available for 24 Hours 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 3
... traumatic brain injuries occur, a speedy diagnosis followed by ... and death. A research team, led by Jason D. ... at the U.S. National Institutes of Health, has created ... such as hematomas, which occur when blood vessels become ...
... have been shown to have higher levels of education ... physically active, and have other characteristics that are associated ... been inconsistent in showing that, after adjustment for all ... of cardiovascular disease and mortality than do consumers of ...
... infant survival rates in 19th -Century Montreal in two ... McGill University. Mother,s milk protected vulnerable infants from food ... the arrival of more siblings and that improved the ... Published in the journal Population Studies , ...
... patterns of emergency care for an entire state has ... Indiana over a three-year period were by patients who ... conventional wisdom that patients are tightly bound to health ... The Regenstrief Institute study, "All Health Care Is ...
... Western Reserve University School of Medicine received a $6.75 ... Diabetes and Digestive and Kidney Diseases (NIDDK) to study ... (IBD). For years, scientists have focused their attention on ... in the cause of Crohn,s disease, a chronic debilitating ...
... they,re thought to be more fearful and feel threatened ... Aviv University shows that the anxious may not be hypersensitive ... enough. As part of a study on how the ... a Ph.D. candidate in TAU,s School of Psychological Sciences and ...
Cached Medicine News:Health News:New device for rapid, mobile detection of brain injury 2Health News:Breastfeeding saved babies in 19th- Century Montreal 2Health News:Breastfeeding saved babies in 19th- Century Montreal 3Health News:First study of emergency care for an entire state finds care isn't always local 2Health News:$6.75 million awarded to Case Western Reserve to study IBD 2Health News:Are the anxious oblivious? 2
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: